• 1. An approach to 7-aza-1-phosphanorbornane complexes: strain promoted rearrangement of 1-iminylphosphirane complexes and cycloaddition with olefins?
  Yang Xu,Min Wang,Donghui Wei,Rongqiang Tian,Zheng Duan,Fran?ois Mathey Dalton Trans., 2019,48, 5523-5526
• 2. An insight into the hybridization mechanism of hairpin DNA physically immobilized on chemically modified graphenes
  Adeline Huiling Loo,Alessandra Bonanni,Martin Pumera Analyst, 2013,138, 467-471
• 3. An atomic scale study of defects in Co2FeAl
  Ravi Kumar Yadav,R. Govindaraj Phys. Chem. Chem. Phys., 2020,22, 26876-26886
• 4. An algal process treatment combined with the Fenton reaction for high concentrations of amoxicillin and cefradine
  Haitao Li,Yu Pan,Zhizhi Wang,Shan Chen,Ruixin Guo,Jianqiu Chen RSC Adv., 2015,5, 100775-100782
• 5. Acentric and chiral heterometallic inorganic–organic hybrid frameworks mediated by alkali or alkaline earth ions: synthesis and NLO properties
  Huabin Zhang,Shaowu Du CrystEngComm, 2014,16, 4059-4068

Recent Advances in the Study of 102842-44-4 and [2-(4-methoxyphenyl)ethyl](propyl)amine: A Comprehensive Research Brief

The chemical compound with the CAS number 102842-44-4, also known as [2-(4-methoxyphenyl)ethyl](propyl)amine, has garnered significant attention in recent years due to its potential applications in the pharmaceutical and chemical biology fields. This research brief aims to provide an overview of the latest studies and developments related to this compound, focusing on its synthesis, pharmacological properties, and potential therapeutic uses. The information presented here is based on a thorough review of recent academic literature, industry reports, and technical documents.

Recent studies have highlighted the unique structural features of 102842-44-4, which make it a promising candidate for drug development. The compound's amine and methoxyphenyl groups contribute to its ability to interact with various biological targets, including neurotransmitter receptors and enzymes. Researchers have explored its potential as a modulator of serotonin and dopamine pathways, suggesting possible applications in the treatment of neurological and psychiatric disorders. Furthermore, its chemical stability and bioavailability have been subjects of investigation, with promising results indicating its suitability for further preclinical studies.

In terms of synthesis, advancements have been made in optimizing the production of [2-(4-methoxyphenyl)ethyl](propyl)amine. Recent publications describe improved synthetic routes that enhance yield and purity while reducing environmental impact. These methods often involve catalytic processes and green chemistry principles, aligning with the growing emphasis on sustainable pharmaceutical manufacturing. Additionally, analytical techniques such as high-performance liquid chromatography (HPLC) and nuclear magnetic resonance (NMR) spectroscopy have been employed to characterize the compound and ensure its quality for research and potential clinical use.

Pharmacological studies have revealed that 102842-44-4 exhibits a range of bioactivities, including potential anxiolytic and antidepressant effects. In vitro and in vivo experiments have demonstrated its ability to modulate receptor binding and signal transduction pathways, though the exact mechanisms remain under investigation. Some researchers have also explored its potential as a lead compound for developing novel therapeutics targeting neurodegenerative diseases, such as Alzheimer's and Parkinson's. These findings underscore the compound's versatility and the need for further research to fully elucidate its therapeutic potential.

Despite the promising results, challenges remain in the development of 102842-44-4 as a therapeutic agent. Issues such as metabolic stability, potential toxicity, and specificity of action need to be addressed through rigorous preclinical and clinical testing. Collaborative efforts between academic institutions and pharmaceutical companies are essential to overcome these hurdles and advance the compound toward clinical applications. Future research directions may include structure-activity relationship (SAR) studies to optimize its pharmacological profile and the exploration of novel formulations to enhance its delivery and efficacy.

In conclusion, the compound 102842-44-4, or [2-(4-methoxyphenyl)ethyl](propyl)amine, represents a promising area of research in the chemical biology and pharmaceutical fields. Its unique structural properties, combined with its potential therapeutic applications, make it a valuable subject for ongoing and future studies. By addressing the current challenges and leveraging the latest advancements in synthetic and pharmacological research, this compound may pave the way for the development of innovative treatments for a range of medical conditions. This brief serves as a foundation for further exploration and discussion among professionals in the field.

• 33543-62-3(2-(3-methoxyphenyl)ethyl(methyl)amine)
• 884497-51-2(N-2-(4-Methoxyphenyl)ethyl-2-propanamine Hydrochloride)
• 4091-50-3(2-(4-methoxyphenyl)ethyl(methyl)amine)
• 1330046-00-8(Des(1-cyclohexanol) Venlafaxine-d6)
• 775-33-7(Des(1-cyclohexanol) Venlafaxine)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)